| Juniper Pharmaceuticals is healthcare company with core businesses consisting of its Crinone® (progesterone gel) franchise. Co. has two segments: product, which oversees the supply chain and manufacturing of Crinone®, an 8.0% progesterone bioadhesive vaginal gel designed for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency; and service, which includes pharmaceutical development, clinical trial manufacturing, and analytical and consulting services for Co.'s customers, as well as characterizing and developing pharmaceutical product candidates for Co.'s internal programs. We show 22 historical shares outstanding datapoints in our coverage of JNP's shares outstanding history.
Understanding the changing numbers of JNP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like JNP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching JNP by allowing them to research JNP shares outstanding history
as well as any other stock in our coverage universe.